Sign up
Pharma Capital

Faron Pharmaceuticals hires chief commercial officer ahead of drug launch

Dr Juhana Heinonen will join the business in January from AstraZeneca
man on a ventilator
The company's flagship drug treats a condition called acute respiratory distress

Faron Pharmaceuticals Oy (LON:FARN), one of a small handful of London-listed drug developers with a product in Phase III clinical trials, said it has appointed a chief commercial officer.

Dr Juhana Heinonen will join the business in January from AstraZeneca PLC (LON:AZN) where he was global marketing director for Fasenra, the company’s asthma treatment.

READ: Faron Pharmaceuticals' £10mln fundraiser will accelerate progress

At Roche, where he worked for seven years to 2015, he oversaw the launch and growth of RoACTEMRA, which eventually became a blockbuster drug for rheumatoid arthritis.

Phase III trial

At Faron, Heinonen will be responsible for the launch and roll out of Traumakine, which is being developed as a life-saving intervention for people with acute respiratory distress. Currently Traumakine is in the late stage of Phase III trials.

Chief executive, Dr Markku Jalkanen, said of the company’s new hire: “He has a wealth of expertise in the commercialisation and marketing of blockbuster drugs, and will be a key addition to the Faron team as we continue our preparations to enter commercialisation.

READ: Faron Pharmaceuticals' lead drug gets significant vote of confidence from UK regulator

“We look forward to benefitting from his experience and valuable insights as our wholly-owned lead product, Traumakine, approaches the completion of its pivotal phase III INTEREST trial."

Ian_55ae0ddd437b7.jpg
Why Invest In Faron Pharmaceuticals Oy? Read More Here

Register here to be notified of future FARN Company articles
View full FARN profile

Faron Pharmaceuticals Oy Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.